ACR Convergence 2025| Video: Rheum for Everyone, Episode 26—Ableism

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

  • Conditions
    • Axial Spondyloarthritis
    • Gout and Crystalline Arthritis
    • Myositis
    • Osteoarthritis and Bone Disorders
    • Pain Syndromes
    • Pediatric Conditions
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
    • Systemic Sclerosis
    • Vasculitis
    • Other Rheumatic Conditions
  • FocusRheum
    • ANCA-Associated Vasculitis
    • Axial Spondyloarthritis
    • Gout
    • Lupus Nephritis
    • Psoriatic Arthritis
    • Rheumatoid Arthritis
    • Sjögren’s Disease
    • Systemic Lupus Erythematosus
  • Guidance
    • Clinical Criteria/Guidelines
    • Ethics
    • Legal Updates
    • Legislation & Advocacy
    • Meeting Reports
      • ACR Convergence
      • Other ACR meetings
      • EULAR/Other
    • Research Rheum
  • Drug Updates
    • Analgesics
    • Biologics/DMARDs
  • Practice Support
    • Billing/Coding
    • EMRs
    • Facility
    • Insurance
    • Technology
      • Information Technology
      • Apps
    • QA/QI
    • Workforce
  • Opinion
    • Patient Perspective
    • Profiles
    • Rheuminations
      • Video
    • Speak Out Rheum
  • Career
    • ACR ExamRheum
    • Awards
    • Career Development
      • Education & Training
    • Certification
  • ACR
    • ACR Home
    • ACR Convergence
    • ACR Guidelines
    • Journals
      • ACR Open Rheumatology
      • Arthritis & Rheumatology
      • Arthritis Care & Research
    • From the College
    • Events/CME
    • President’s Perspective
  • Search

Search results for: cancer

COVID-19 Vaccination Induces T Cell Response in Patients Treated with Rituximab

Lara C. Pullen, PhD  |  September 14, 2021

Research indicates mRNA vaccination for SARS‐CoV‐2 infection may induce a T cell response in vulnerable, immunocompromised patient populations being treated with rituximab.

Filed under:Conditions Tagged with:COVID-19rituximabvaccination

In Memoriam: Ronald Olejko—May 4, 1950–Sept. 5, 2021

Keri Losavio  |  September 7, 2021

Ronald Frank Olejko (71)—who many ACR/ARP members knew as the man who managed the smooth planning and execution of the ACR’s annual meeting for more than 40 years—passed away on Sunday, Sept. 5, after a long battle with bladder and kidney cancer. He died peacefully at home with friends and loved ones by his side….

Filed under:From the CollegeProfiles Tagged with:OlejkoRon Olejko

FDA Requires New Boxed Warnings on JAK Inhibitors, Places Restrictions on Use

Keri Losavio  |  September 1, 2021

On Sept. 1, the U.S. Food & Drug Administration (FDA) announced that it is requiring revisions to the Boxed Warning for the Janus kinase (JAK) inhibitors Xeljanz/Xeljanz XR (tofacitinib), Olumiant (baricitinib) and Rinvoq (upadacitinib) to include information about the risks of serious heart-related events, cancer, blood clots and death.1 Recommendations for healthcare professionals will include…

Filed under:Drug Updates Tagged with:baricitinibJAK inhibitorsjakinibsTofacitinibupadacitinib

AbbVie, Lilly Face New Delays in FDA Approval for Expanded Use of Janus Kinase Inhibitors

Natasha Yetman  |  July 26, 2021

(Reuters)—AbbVie Inc. and ELi Lilly & Co. are facing fresh delays in the approval of their respective rheumatoid arthritis (RA) drugs for treating the chronic skin disease eczema as the U.S. health regulator assesses the new class of treatment over safety concerns. The treatment, called Janus kinase inhibitors (jakinibs), blocks inflammation-causing enzymes known as Janus…

Filed under:Drug Updates Tagged with:FDAFDA approvalJAK inhibitorsjakinibU.S. Food and Drug Administration (FDA)

CDC Advisers Consider Boosters for Immune-Compromised Americans

Julie Steenhuysen  |  July 26, 2021

CHICAGO (Reuters)—Advisers to the U.S. Centers for Disease Control & Prevention will consider evidence suggesting that a booster dose of COVID-19 vaccines could increase protection among people with compromised immune systems. Data presented ahead of the July 22 meeting noted that people with compromised immune systems have a reduced antibody response following the recommended primary…

Filed under:Drug Updates Tagged with:CDCCenters for Disease Control and PreventionCOVID-19vaccines

Webside Care Can Enhance Rheumatology Training & Patient Satisfaction

Lisa Zickuhr, MD, Jason Kolfenbach, MD, & Marcy B. Bolster, MD  |  July 15, 2021

Many practitioners can relate to the epiphany of Roy Basch, MD, the lead character in Samuel Shem’s satirical novel The House of God.1 During his first on-call shift as a medicine intern, long work hours combined with jaded advice from his senior resident leave Dr. Basch feeling disenchanted with the medical profession until he cares…

Filed under:Education & TrainingPatient Perspective Tagged with:telemedicinewebside care

Researchers Explore Response to COVID-19 Vaccines in the Elderly

Ruth Jessen Hickman, MD  |  July 6, 2021

A delayed second dose of an mRNA vaccine may provide better protection against COVID-19 in elderly patients.

Filed under:Conditions Tagged with:COVID-19elderlyimmunosenescencevaccinationvaccine

High Cost of Specialty Drugs Demands Action

Mary Beth Nierengarten  |  July 6, 2021

Amid rising drug costs and the growing influence of pharmacy benefit managers on patient care decisions, physicians are increasingly called upon to advocate for affordable, evidence-based treatments for their patients.

Filed under:Legislation & AdvocacyPractice Support Tagged with:drug pricingpharmacy benefit managers (PBMs)

Grinding Away: An Overview of Progress in the Treatment & Management of Osteoarthritis

Jason Liebowitz, MD, FACR  |  June 28, 2021

Convex-walking shoes, dietary supplements, advancements in nerve growth factor inhibitors and more—Xavier Chevalier gave an overview and new insights into treatments for osteoarthritis.

Filed under:ConditionsEULAR/OtherMeeting ReportsOsteoarthritis and Bone Disorders Tagged with:dietary supplementEULARhandhand osteoarthritisKnee Osteoarthritis (OA)osteoarthritis (OA)

Are Medicare Beneficiaries with Knee OA Receiving Enough Conservative Care?

Marilynn Larkin  |  June 22, 2021

NEW YORK (Reuters Health)—Non-surgical care for knee osteoarthritis (OA) is uncommon among older adults, especially in regions of the U.S. where total knee arthroplasty rates are high, a large retrospective analysis shows.1 “As rheumatologists, we often think of knee arthroplasty as the last resort, after patients have tried and failed more conservative treatments, such as…

Filed under:ConditionsOsteoarthritis and Bone DisordersResearch Rheum Tagged with:Arthritis & RheumatologyKnee Osteoarthritis (OA)patient caretotal knee arthroplasty

  • « Previous Page
  • 1
  • …
  • 18
  • 19
  • 20
  • 21
  • 22
  • …
  • 86
  • Next Page »
  • About Us
  • Meet the Editors
  • Issue Archives
  • Contribute
  • Advertise
  • Contact Us
  • Copyright © 2026 by John Wiley & Sons, Inc. All rights reserved, including rights for text and data mining and training of artificial technologies or similar technologies. ISSN 1931-3268 (print). ISSN 1931-3209 (online).
  • DEI Statement
  • Privacy Policy
  • Terms of Use
  • Cookie Preferences